Review Article
Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin
Table 2
Summary of efficacy results of trabectedin in advanced uterine leiomyosarcoma.
| | Study | Regimen | Evaluable patients () | Prior regimens Median
(range) | ORR | DCR | Median PFS
(months) | 3-month PFS | 6-month PFS | Median OS
(months) | 12-month OS | 24-month OS |
| | Phase II GOG study [49] | Trabectedin | 20 | 0 | 10% | 60% | 5.8 | NR | NR | 26.1+ | NR | NR | | Phase II LMS-02 study [50] | Trabectedin/doxorubicin | 47 | 0 | 59.6% | 87.2% | 8.2 | 87% | NR | 20.2 | NR | NR | | Pooled analysis [51] | Trabectedin | 62 | 2 (0–6) | 17.7% | 53.2% | 2.5 | 46.4% | 30.8% | 12.1 | 51.6% | 20.3% | | Retrospective analysis [52] | Trabectedin | 66 | 3 (1–5) | 16% | 51% | 3.3 | 53% | 33% | 14.4 | NR | NR |
|
|
DCR: disease control rate; GOG: Gynecologic Oncology Group; NR: not reported; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; U-LMS: uterine leiomyosarcoma.
|
